University of Ioannina
Ανάπτυξη νέας γενιάς αντι-αιμοπεταλιακών παραγόντων με συνδυαστική παρέμβαση σε διαφορετικά μονοπάτια ενεργοποίησης και συσσώρευσης των ανθρώπινων αιμοπεταλίων
Abstract
dc:descriptionThe high sensitivity of platelets to various pathophysiological conditions made them one of the most accessible biomarkers. Through the action of their receptors, they are activated, acting as adhesion molecules that interact with the damaged endothelium, or with other platelets and leukocytes. Therefore, platelet activation and eventually clot formation has been associated with the action of specific receptors on their cell membrane.Our research focused on transmembrane platelet receptors and specifically the transmembrane multidrug resistance protein-4 (MRP4). In general, the MRP4 protein in the cell which expressed, acts as a broad-spectrum efflux pump of substrates, including nucleoside analogs, antiviral and antiplatelet drugs such as aspirin. The extrusion process requires energy, which is obtained by the hydrolysis of ATP. Hydrolysis takes place in the two intracellular domains of the protein, by binding ATP to specific amino acid sequences of each subunit. The sequences involved in the binding and hydrolysis of ATP are reported in references as Walker A, C-motif, and Walker B.Especially, the MRP4 protein in platelets is expressed both in their cell membrane and in the membrane of intraplatelet organelles, the δ-granules. The protein is involved in platelet activation and accumulation by participating in the metabolic pathway of cAMP, in two ways. Either it stores cAMP in the δ-granules (MRP4 dense granules) or it is extruding from the cell (membraned MRP4). The efflux of cAMP, which acts as a signal for neighboring platelets to be activated, in conjunction with the reduction of cAMP intraplatelet, due to its storage in the d-granules, contributes to the activation of platelets. In conclusion, the action of MRP4 in platelets is cAMP-dependent and therefore the inhibition of MRP4 will inhibit platelet activation and accumulation.The purpose of this study is to inhibit the activation and accumulation of human platelets through the development of appropriate new generation peptide anti-platelet agents based on the parent sequence of the intracellular domain of MRP4. To succeed this purpose, MRP4 peptides analogs were carefully selected and synthesized, bearing in their sequence the protein-functional Walker A, C-motif, and Walker-B motifs. Also, peptide analogs were selected to synthesize, based on sequences of intracellular MRP4 subunits, in which the interaction of specific amino acid residues aid in modulatory protein modification for substrate efflux. Finally, the peptide analogs were ligated, via thioether bond, with peptide carriers Τat(48-60)-Cys and Ac-CPSOC, which penetrate the cell membrane, for intracellular targeting of platelet activation and accumulation.After synthesis and purification of the complexes, between carriers and peptide analogs of MRP4, platelet function testing was performed for identification of inhibitory effect on platelet activation and accumulation in washed human platelets and platelet-rich plasma. To simulate the cAMP metabolic pathway in platelets, experiments were performed with or without the presence of prostaglandin PGE1. The concentration of PGE1 used was such as to cause a maximum of 10-11% of total inhibitory activity. Finally, possible combined intervention in other pathways of platelet activation and accumulation was investigated, through flow cytometry experiments.Initially, studies of cell-penetrating carriers have shown that the peptide carrier Tat(48-60)-Cys(Acm) inhibits platelet aggregation in both washed platelets and platelet-rich plasma and association with the use of PGE1 prostaglandin. In combination with the results of flow cytometry and inhibition of fibrinogen binding, it demonstrates activity against platelet function, which may be characterized by a possible non-specific extracellular activity in addition to its known intracellular activity. Ac-CPSOC, on the other hand, did not affect platelet activation, in washed platelets, or platelet-rich plasma, with or without the use of prostaglandin. This result, combined with the lack of action in flow cytometry experiments, show that the Ac-CPSOC carrier has no activity in platelet function, either extracellularly and possibly intracellularly. We conclude, therefore, that the occurrence of Ac-CPSOC activity is related to the activity of the biological cargo with which is conjugated. This can be the basis for the design of intracellular inhibitors. Thus, the Ac-CPSOC carrier is an important tool for shifting bio-cargoes intracell, especially to sensitive cells such as platelets, without parallel from carrier interactions in cell function. Subsequently, biological study (aggregation tests and flow cytometry) of the MRP4 peptide analogs conjugated with the carriers, since the Ac-CPSOC does not inhibit platelet activation, showed that two MRP4 peptide analogs have an inhibitory effect on platelet function. Their interaction with the active carrier Tat(48-60)Cys(Acm), confirmed the initial hypothesis, and also an enhancement of its inhibitory effect was observed by studying the synergists in the presence of prostaglandin PGE1. This led to the conclusion that the active peptide analogs that emerged from their interaction with the Ac-CPSOC carrier probably acted synergistically with the Tat(48-60)-Cys(Acm) carrier and synergistically with prostaglandin in the platelet operation.In conclusion, this study revealed for the first time, a new antiplatelet approach through the development of a new generation of peptide natured antiplatelet agents, derived from the MRP4 protein, with intracellular targeting. These new inhibitors could potentially act as non-specific inhibitors in different pathways of platelet activation and accumulation, inhibiting their intracellular activation synergistically with the prostaglandin PGE1, but also the binding of fibrinogen in the active state of αIIbβ3 integrin receptor.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Angelis, Ioannis
- Αγγελής, Ιωάννης
Subjects
dc:subject × 24- MRP4/ABCC4
- Πολυφαρμακευτική αντίσταση
- Αντι-αιμοπεαλιακή στόχευση
- Ασπιρίνη
- cAMP-διαμερισματοποίηση
- Αιμοπετάλια
- Αναστολή συσσώρευσης αιμοπεταλίων
- Multidrug resistance (MDR)
- Antiplatelet target
- Aspirin
- cAMP-compartmentalization
- Blood platelets
- Χημεία
- Φυσικές Επιστήμες
- Χημεία, άλλοι τομείς
- Επιστήμες Υγείας
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες υγείας, γενικά
- Chemical Sciences
- Natural Sciences
- Chemistry, miscellaneous
- Health Sciences
- Medical and Health Sciences
- Health sciences, general
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/49244